Wednesday, June 21, 2017 8:42:44 AM
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring
BY PR Newswire
— 7:05 AM ET 06/21/2017
MARLBOROUGH, Mass., June 21, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) , a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today the completion of enrollment in its Phase 1/2 study RXI-109-1501. This multi-center, multi-dose, dose escalation trial is being conducted in patients with advanced neovascular or 'wet' age-related macular degeneration (AMD) where retinal scarring can result in continued vision loss. RXI-109 is a self-delivering RNAi (sd-rxRNA®) compound developed to target connective tissue growth factor (CTGF), a key regulator of scar formation.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
"We are very pleased with the progress of this clinical trial and happy to report that RXI-109 has been well tolerated with no drug related issues occurring to date," said Dr. Gerrit Dispersyn, Chief Development Officer of RXi Pharmaceuticals. He continued, "The completion of enrollment is an important study milestone as this means that we are likely to finish patient follow-up before year end, as planned and previously communicated."
The primary endpoint for RXI-109-1501 is to evaluate the safety and tolerability of RXI-109, but in the study other endpoints are included to assess RXI-109's potential for clinical activity using numerous assessments to monitor ocular health and visual acuity. In this Phase 1/2 study, each subject receives a total of four doses of RXI-109 at one month intervals. RXI-109 is administered by intravitreal injection in one eye only. The dosing period (3 months) is followed by a four month observation period. Several dose levels are evaluated in a small number of subjects in this first trial in order to establish safety information and to help determine the dosing regimen for continued study.
Recent PHIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 07:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 06:59:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:11:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:14:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:00:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:45:46 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 01:05:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/05/2024 12:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:00:10 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 08:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 09:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/20/2024 09:03:23 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/20/2024 08:59:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/17/2024 08:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 01:04:34 PM
- Phio Pharmaceuticals Secures New Investor • GlobeNewswire Inc. • 05/17/2024 01:00:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 01:00:13 PM
- Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study • GlobeNewswire Inc. • 05/15/2024 05:00:00 PM
- Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 09:25:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:21 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM